Lataa...

177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial si...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Majid Assadi, Hojjat Ahmadzadehfar
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-10-01
Sarja:World Journal of Nuclear Medicine
Aiheet:
Linkit:http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_112_18
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!